Charles Bankhead

The cardiac risks associated with conventional chemotherapy and radiotherapy are well established. What has been learned so far about newer treatments, such as targeted agents and immunotherapy? Have any cardiac issues arisen with those types of treatment? #Cardiooncoconnect

Dr. Scott, I understand that you attended a meeting of the Canadian cardio-oncology community last week. Can you share some of the insights you gained from that meeting? #Cardiooncoconnect

Hi all. Charles Bankhead, Senior Editor, Oncology #Cardiooncoconnect

What about managing CV risk factors in these patients? Follow the same recommendations as other people with hypertension, dyslipidemia, etc.? #CardioOncoConnect

Are there guidelines or recommendations for managing CV risk in patients on ADT? What tests/labs and how often? #CardioOncoConnect

Is the CV risk with orchiectomy similar to what is seen with medical castration? #CardioOncoConnect

I'm Charles Bankhead, Sr Associate Editor for oncology. #CardioOncoConnect

Thank you, Dr. Rugo and Dr. Lopez-Mattei for sharing some of your timem with us today. #CardioOncoConnect

I meant to say "other types of cancer" #cardiooncoconnect

Dr. Lopez-Mattei, we've been talking about breast cancer for the most part. Are there are types of cancer that have a risk of treatment-related cardiotoxicity?#cardiooncoconnect

To get back to the question I asked earlier, what did you think of the prevention study that was reported at SABCS, Dr. Rugo? #cardiooncoconnect

Dr. Rugo, did you see the prevention study reported at SABCS? If so, what did you take away from the results? #cardiooncoconnect

I'm Charles @CBankheadMPT , Sr. Assoc. Editor for Oncology at MedPage Today #cardiooncoconnect

Radiation oncologists have a lot to say about studies reported #ASTRO14. See for yourself. http://t.co/bvbOtrnPrI

Radiation therapy gets a vote of confidence as treatment for high-risk prostate cancer.#ASTRO14 http://t.co/aa1Vke0X9D

Declining use of radiation therapy for early Hodgkin's lymphoma despite good outcomes.#ASTRO14 http://t.co/x0KFnLQzrw

Lots of interest in study by Slotman et al showing improved 2-year survival with chest RT for advanced SCLC.#ASTRO14